11 October 2023

Scancell Holdings plc

("Scancell" or the "Company")

Change of Date for Final Results and Investor Presentation

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces a revised date for the publication of its results for the year ended 30 April 2023.

The audit of the Group's Annual Report & Accounts is well advanced, however, the Group's auditor, BDO LLP, has requested more time to complete their standard audit. As a result, the Company will now announce its results on 24 October 2023, a delay to the previously planned date of 12 October 2023.

Professor Lindy Durrant, Chief Executive Officer, and Sath Nirmalananthan, Chief Financial Officer, will host an analyst briefing at 10:00am BST on the revised date of the results at the offices of ICR Consilium, 85 Gresham St, London, EC2V 7NQ.

The Company will also be holding a presentation for investors on 24 October 2023 at 4:30pm BST via the Investor Meet Company platform.

The presentation is open to all existing and potential shareholders and will be followed by a Q&A session. Questions can be submitted ahead of the event via the Investor Meet Company dashboard up until 9.00am BST on 23 October 2023, or at any time during the live presentation.

To sign up to Investor Meet Company for free and add to register for Scancell's presentation , please visit: https://www.investormeetcompany.com/scancell-holdings-plc/register-investor

A copy of the presentation will also be made available on the Company's news section following the presentation.

-ENDS-

About Scancell

Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope^® and ImmunoBody^® for vaccines and GlyMab^® and AvidiMab^® for antibodies.

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope^® and ImmunoBody^®) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab^®) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab^®).

For further information about Scancell, please visit: https://www.scancell.co.uk/